222 related articles for article (PubMed ID: 21246613)
1. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
[TBL] [Abstract][Full Text] [Related]
2. Embelin inhibits growth and induces apoptosis through the suppression of Akt/mTOR/S6K1 signaling cascades.
Kim SW; Kim SM; Bae H; Nam D; Lee JH; Lee SG; Shim BS; Kim SH; Ahn KS; Choi SH; Sethi G; Ahn KS
Prostate; 2013 Feb; 73(3):296-305. PubMed ID: 22887478
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis.
Wang X; Bai H; Zhang X; Liu J; Cao P; Liao N; Zhang W; Wang Z; Hai C
Carcinogenesis; 2013 Jun; 34(6):1323-30. PubMed ID: 23404993
[TBL] [Abstract][Full Text] [Related]
4. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways.
Gazitt Y; Kolaparthi V; Moncada K; Thomas C; Freeman J
Int J Oncol; 2009 Feb; 34(2):551-61. PubMed ID: 19148492
[TBL] [Abstract][Full Text] [Related]
5. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin inhibits tumor growth of human osteosarcomas.
Zhao S; Lu N; Chai Y; Yu X
J BUON; 2015; 20(2):588-94. PubMed ID: 26011354
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor cell growth, proliferation and migration by X-387, a novel active-site inhibitor of mTOR.
Chen SM; Liu JL; Wang X; Liang C; Ding J; Meng LH
Biochem Pharmacol; 2012 May; 83(9):1183-94. PubMed ID: 22305748
[TBL] [Abstract][Full Text] [Related]
8. Xiao Jin Wan, a traditional Chinese herbal formula, inhibits proliferation via arresting cell cycle progression at the G2/M phase and promoting apoptosis via activating the mitochondrial‑dependent pathway in U-2OS human osteosarcoma cells.
Wu G; Chu J; Huang Z; Ye J; Chen P; Zheng C; Li X; Liu X; Wu M
Int J Oncol; 2013 Mar; 42(3):1070-80. PubMed ID: 23354363
[TBL] [Abstract][Full Text] [Related]
9. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma.
Peponi E; Drakos E; Reyes G; Leventaki V; Rassidakis GZ; Medeiros LJ
Am J Pathol; 2006 Dec; 169(6):2171-80. PubMed ID: 17148679
[TBL] [Abstract][Full Text] [Related]
10. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
Evangelisti C; Ricci F; Tazzari P; Tabellini G; Battistelli M; Falcieri E; Chiarini F; Bortul R; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Leukemia; 2011 May; 25(5):781-91. PubMed ID: 21331075
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of glucose transporter-1 in vascular smooth muscle cells via the Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) pathway in experimental renal failure.
Lin CY; Hsu SC; Lee HS; Lin SH; Tsai CS; Huang SM; Shih CC; Hsu YJ
J Vasc Surg; 2013 Feb; 57(2):475-85. PubMed ID: 23265586
[TBL] [Abstract][Full Text] [Related]
12. Caffeine induces apoptosis of osteosarcoma cells by inhibiting AKT/mTOR/S6K, NF-κB and MAPK pathways.
Miwa S; Sugimoto N; Yamamoto N; Shirai T; Nishida H; Hayashi K; Kimura H; Takeuchi A; Igarashi K; Yachie A; Tsuchiya H
Anticancer Res; 2012 Sep; 32(9):3643-9. PubMed ID: 22993301
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
Chandrasekher G; Sailaja D
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
[TBL] [Abstract][Full Text] [Related]
14. LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms.
Kristof AS; Pacheco-Rodriguez G; Schremmer B; Moss J
J Pharmacol Exp Ther; 2005 Sep; 314(3):1134-43. PubMed ID: 15923340
[TBL] [Abstract][Full Text] [Related]
15. Physakengose G induces apoptosis via EGFR/mTOR signaling and inhibits autophagic flux in human osteosarcoma cells.
Lin H; Zhang C; Zhang H; Xia YZ; Zhang CY; Luo J; Yang L; Kong LY
Phytomedicine; 2018 Mar; 42():190-198. PubMed ID: 29655686
[TBL] [Abstract][Full Text] [Related]
16. Sex determining region Y-box 2 inhibits the proliferation of colorectal adenocarcinoma cells through the mTOR signaling pathway.
Liu H; Du L; Wen Z; Yang Y; Li J; Dong Z; Zheng G; Wang L; Zhang X; Wang C
Int J Mol Med; 2013 Jul; 32(1):59-66. PubMed ID: 23599173
[TBL] [Abstract][Full Text] [Related]
17. Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma.
Jiang H; Zeng Z
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):255-61. PubMed ID: 26514724
[TBL] [Abstract][Full Text] [Related]
18. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
19. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
Paternot S; Roger PP
Cancer Res; 2009 Jun; 69(11):4577-81. PubMed ID: 19458076
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
